Jianmin Mao

🗞 Breaking news 🤩 Genezen acquire uniQure's commercial GT manufacturing ops in Lexington!! This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Check out full article below👇 #CDMO #Genezen #GeneTherapy

18

💊 Industry News Roundup 💊 🧠 Scientists, at Epoch Biotech, have discovered a new genetic clue for delaying Alzheimer's - this has been inspiring drug discovery and could be ground-breaking. 💲 Emergent BioSolutions sold their Baltimore facility for $30M to Bora Pharmaceuticals, which included 350 of Emergent's employees 🔥 Novo Nordisk office building in Denmark, set fire again. This is the third time in the last month - everyone was safe. ➕ Zealand Pharma hits early efficacy goal for amylin weight loss candidate - another movement in the obesity space 👀 😢 Cara Therapeutics have had to cut their workforce after trial failure 😍 iOnctura raises 80M to advance early-stage eye cancer treatment 👁 ❤️ Silence Therapeutics plc siRNA candidate for cardiovascular disease is continuing to deliver in Phase 2 trials!!! 💲 The target is set for new obesity biotech UroGen Pharma, aiming to raise over $107M 🐥 A tweet about a gene led a start-up called Marea raise $190M to develop a drug to lower a type of cholesterol, a new way of maybe attacking cardiovascular disease An exciting time in the biotech space, and if you haven't already - give our podcast The BioHub Podcast a follow.

11

1 Comment

🌟 Exciting News from BeiGene! 🌟 BeiGene unveiled its flagship biologics manufacturing and R&D center in Hopewell, New Jersey! This new 42-acre campus signifies a major step forward in innovation and partnerships in the biologics space. 🏢🔬 Key Highlights: -State-of-the-Art Facility: The site features 400,000 sq. ft. of commercial production space, with a capacity for 2 million vials per year and room for future expansion. 🌐 -Strategic Location: Originally owned by Bristol Myers Squibb, the campus provides a robust infrastructure for growth. 📍 -Collaboration Potential: CEO John Oyler is optimistic about new partnerships, emphasizing BeiGene's capabilities in co-development and co-commercialization. 🤝 Supporting Tevimbra: The new site will play a pivotal role in the launch of BeiGene's first biologic product in the U.S., the PD-1 inhibitor Tevimbra. This ensures timely FDA inspections and reliable production. 🚀 Global Reach: BeiGene continues to expand its footprint, combining deep roots in China with a strong presence in the U.S. and beyond. 🌍 With the opening of this advanced facility, BeiGene is poised for exciting new collaborations and breakthroughs in biologics. Stay tuned for more updates! #Biotech #Innovation #Biologics #Pharma #Partnerships #Healthcare #ResearchAndDevelopment #BeiGene #GlobalExpansion #Tevimbra #HopewellNJ 📸: BeiGene CEO John Oyler and NJ Governor Phil Murphy celebrating the opening of the Hopewell site.

1

1 Comment

Harris vs. Trump: What the Presidential Election Could Mean for the Biopharma Industry As the 2024 election approaches, the close race between Vice President Kamala Harris and former President Donald Trump is sparking significant discussion about potential impacts on the biopharma sector. Analysts and industry stakeholders are weighing in on key issues like drug pricing reforms and regulatory policies that could shape biopharma's future under either administration. 🔴Potential Impacts Under a Trump Administration 🔴 Some believe a second Trump term could favor biopharma. According to BMO Capital Markets analysts Evan Seigerman and Kostas Biliouris, PhD, the industry might benefit from: 🔴Inflation Reduction Act Stability: The IRA may not expand and could be repealed. 🔴Less FTC Scrutiny: Potential decrease in Federal Trade Commission oversight on biopharma. 🔴Drug Pricing Reforms Targeting PBMs: Reforms may focus on pharmacy benefit managers (PBMs) over manufacturers. However, Trump's stance on drug pricing has been unpredictable. He has supported measures like price controls, not typically aligned with Republican positions, adding uncertainty for the industry. 🔵 Potential Impacts Under a Harris Administration 🔵 Vice President Harris's plan focuses on tackling high drug prices by addressing both PBMs and pharmaceutical companies. Key aspects include: 🔵 Cracking Down on Anti-Competitive Practices: Targeting practices that inflate drug prices. 🔵 Accelerating Medicare Negotiations: Speeding up talks to reduce medication costs faster. 🔵 Potential Use of "March-In Rights": Considering invoking Bayh-Dole Act provisions for reasonable pricing on federally funded drugs. While these measures aim to lower costs, some industry experts express concerns about unintended consequences. Invoking march-in rights could affect pharma-academic partnerships, potentially impacting innovation. The Industry at a Crossroads As election day nears, the biopharma industry is closely monitoring developments. The outcome could significantly influence regulatory policies, drug pricing reforms, and the business environment for pharmaceutical companies. Looking Ahead Regardless of the election outcome, biopharma will continue to face challenges in drug pricing, innovation, and regulation. Stakeholders are encouraged to engage in dialogue to find balanced solutions that promote both public health and industry growth. Join the Conversation What are your thoughts on how the election might impact biopharma? How do you see policies shaping the future of drug pricing and innovation? Share your perspectives below. Here a great article from BioSpace on this topic: https://lnkd.in/dv7dyphx

1

Astellas Pharma's FDA approval for Vyloy (zolbetuximab) is a pivotal development in the gastric cancer landscape. As the first therapy targeting CLDN18.2, it carves a niche in an underserved market. The competitive landscape is heating up, with several companies like Zai Lab, Innovent, and BioNTech exploring CLDN18.2-targeting drugs. Vyloy's success will likely prompt a race among these biopharma players to accelerate their clinical pipelines. This approval signals a larger shift in oncology toward biomarker-driven treatments, advancing personalized medicine in gastric cancer—a field traditionally lacking targeted therapies. Competitors might need to innovate rapidly to maintain a foothold. The industry impact is substantial, as new combination treatments involving Vyloy may set the standard for advanced-stage gastric cancer. This could increase R&D focus on biomarker-based treatments and alter the landscape for existing chemotherapy regimens. The introduction of Vyloy underscores the significance of CLDN18.2 as a new therapeutic target, potentially encouraging further collaboration or competition in precision oncology. #Astellas #FDAApproval #GastricCancer #Biotech #PharmaInnovation #PrecisionOncology #Pharmaceuticals #CancerTreatment #OncologyBreakthrough #PersonalizedMedicine #LifeSciences #TylerLakeConsulting #ExecutiveRecruitment

5

Drama in Pharma: AbbVie vs. BeiGene Heats Up In the high-stakes world of biotech, AbbVie has filed another lawsuit against BeiGene, alleging theft of trade secrets related to a groundbreaking blood cancer therapy. AbbVie claims that a former scientist, now at BeiGene, shared proprietary information about its BTK degrader, ABBV-101, which competes with BeiGene’s BGB-16673. With BeiGene’s treatment receiving FDA Fast Track status, the stakes are higher than ever. This dispute is about more than just patents—it's a battle for leadership in the next generation of cancer treatments, where innovation and market control go hand-in-hand. Both companies are pushing for dominance in the blood cancer space, and this lawsuit adds a new layer of complexity to an already competitive landscape. As these legal challenges unfold, one has to wonder: Do these lawsuits help or hinder the pace of innovation in biotech? Can the need to protect intellectual property coexist with a culture of collaboration, or does competition inevitably lead to conflict? #Pharma #Biotech #Innovation #Leadership #LegalBattles #Oncology #DramainPharma #Executiverecruitment #Recruiting #TylerLakeConsulting

3

🚀 Ginkgo Bioworks, Inc. Bioworks Sets Date for Q2 2024 Results Presentation 🚀 📅 Presentation Date: Thursday, August 8, 2024, at 5:30 PM ET. Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced a presentation and Q&A session to review its business performance for the second quarter ended June 30, 2024. The session will be held post-market on August 8, 2024. About Ginkgo Bioworks: Ginkgo Bioworks is a leader in cell programming and biosecurity, offering end-to-end services for various markets, including food, agriculture, pharmaceuticals, and specialty chemicals. Their biosecurity division focuses on developing infrastructure and technologies to predict and respond to biological threats. #GinkgoBioworks #Q2Results #InvestorUpdate #Biotech #Biosecurity #CellProgramming #Innovation #GinkgoResults

2

1 Comment

How do you simplify to amplify to motivate and inspire your teams to thrive? We recently sat down with Franco Davi to glean wisdom and learn of his best practices on how he has been a effective leader through the good and challenging times. Check out our podcast! #thoroughlythriving #leadership #Biotech #innovation

10

The Q3 Job Market Report from BioSpace just dropped, and you definitely want to check it out! The life sciences job market is going through some big changes, and keeping up with the latest info is super important for navigating it all. According to the new BioSpace data, there are some challenges but also plenty of opportunities coming up! 🔍 Key Insights from BioSpace's Q3 2024 Report: 1. Decrease in Job Postings:   - There were 21,548 jobs live on BioSpace in Q3 2024.   - This is a 12% decrease from 24,503 jobs in Q3 2023. 2. Increase in Job Competition:   - The job response rate (percentage of people applying after viewing) jumped from 9.8% to 14.8%, a 51% increase year-over-year.   - Notably, from July to September 2024, the response rate surged from 14.5% to 18.4%, a 26.9% increase. 3. Top States for Job Openings:   - California: 3,769 jobs   - Massachusetts: 3,110 jobs   - New Jersey: 2,513 jobs   - Illinois: 2,452 jobs   - New York: 1,717 jobs 4. Impact of Layoffs:   - In Q3 2024, there were 54 rounds of layoffs in biotech and pharma, affecting at least 3,700 employees.   Significant layoffs included:    - FibroGen, Inc.: Let go of 75% of its U.S.-based workforce (~356 people).    - GRAIL: Laid off about 350 employees.    - BioMarin Pharmaceutical Inc.: Cut 225 positions globally.    - Johnson & Johnson & Bayer: Combined layoffs of 288 employees in New Jersey. 💡 What This Means for You: - Increased Competition: With fewer job postings and more professionals in the market, it's crucial to differentiate yourself. - Strategic Job Hunting: According to Carina Clingman, PhD, CEO of Recruitomics Consulting, fall is prime time for job hunting in biotech. Companies aim to fill positions before the budget cycle ends around Thanksgiving. 📈 Emerging Opportunities:  - Johnson & Johnson is investing $2 billion in a new biologics manufacturing plant in Wilson, North Carolina, expected to create 420 new full-time, highly skilled jobs. Construction begins in the first half of 2024.  - Eli Lilly and Company is committing $4.5 billion to build a facility in Lebanon, Indiana, housing research and manufacturing. Set to open in late 2027, it will employ about 400 new engineers, scientists, lab technicians, and operations personnel.  - MassBio's 5-Year Plan: Aiming to create hundreds of new biopharma and life sciences positions in Massachusetts by 2030, focusing on supporting early-stage biotech growth. 🚀 Tips to Stay Ahead: - Update Your Skills: Leverage this time to enhance your expertise and stay competitive. - Network: Engage with industry peers and attend virtual or in-person events. - Stay Informed: Keep an eye on emerging biotech hubs and companies expanding their workforce. - Be Proactive: Tailor your applications and highlight how you can add value in this dynamic environment. Share your experiences or tips below. #Biotech #Pharma #JobMarket #CareerGrowth #LifeSciences

4

Marengo Therapeutics and Ipsen are joining forces again, with a major deal to advance precision T-cell engagers from Marengo's STAR platform. This partnership includes an upfront payment and potential milestone payments soaring up to $1.2 billion, plus tiered royalties. This agreement builds upon a prior T cell engager collaboration from 2022, where Ipsen paid $45 million upfront and committed up to $1.6 billion in milestone payments. Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in a new early development collaboration. Research will focus on reinvigorating and mobilizing selective Vβ T cells to boost anti-tumor activity in patients with traditionally difficult-to-treat ‘cold’ tumors. This is a significant leap forward, leveraging Marengo’s innovative T-cell activation technology and Ipsen’s global oncology reach. The STAR platform’s ability to precisely target and enhance T-cell responses could revolutionize cancer treatment, making therapies more effective and long-lasting with fewer side effects. For the biotech community, this is a strong indication that precision immuno-oncology is making headway. Both companies have a history of successful collaboration, and this deal underscores their commitment to pushing the boundaries of cancer treatment. Looking forward to seeing how this partnership unfolds and the potential impact on oncology! 𝐹𝑜𝑟 𝑚𝑜𝑟𝑒 𝑑𝑒𝑡𝑎𝑖𝑙𝑠, 𝑟𝑒𝑎𝑑 𝑡ℎ𝑒 𝑓𝑢𝑙𝑙 𝑝𝑟𝑒𝑠𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑓𝑟𝑜𝑚 𝐼𝑝𝑠𝑒𝑛 - ℎ𝑡𝑡𝑝𝑠://𝑤𝑤𝑤.𝑖𝑝𝑠𝑒𝑛.𝑐𝑜𝑚/𝑝𝑟𝑒𝑠𝑠-𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑠/𝑖𝑝𝑠𝑒𝑛-𝑎𝑛𝑑-𝑚𝑎𝑟𝑒𝑛𝑔𝑜-𝑡ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐𝑠-𝑎𝑛𝑛𝑜𝑢𝑛𝑐𝑒-𝑠𝑒𝑐𝑜𝑛𝑑-𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑖𝑐-𝑝𝑎𝑟𝑡𝑛𝑒𝑟𝑠ℎ𝑖𝑝-𝑡𝑜-𝑎𝑑𝑣𝑎𝑛𝑐𝑒-𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛-𝑡-𝑐𝑒𝑙𝑙-𝑒𝑛𝑔𝑎𝑔𝑒𝑟𝑠-𝑓𝑟𝑜𝑚-𝑚𝑎𝑟𝑒𝑛𝑔𝑜𝑠-𝑡𝑟𝑖-𝑠𝑡𝑎𝑟-𝑝𝑙𝑎𝑡𝑓𝑜𝑟𝑚/

4

🔄 Merck & Co. Makes Strategic Moves in ADC Pipeline with Kelun-Biotech 💊💥 In a significant pipeline update, Merck & Co. is making waves in the antibody-drug conjugate (ADC) space! Merck has exercised its option on SKB571, a promising bispecific ADC targeting solid tumors like lung and gastrointestinal cancers, with a $37.5M payment to Kelun-Biotech. 💰🔬 While advancing SKB571, Merck has also opted to return the global rights to another ADC, SKB315, which targets CLDN18.2—a crowded field with multiple contenders. Kelun will continue to develop SKB315, focusing on the Chinese market, where early data shows positive results in gastric cancer. 📈🌍 This move sharpens Merck's focus on high-potential assets while streamlining its ADC portfolio. With the ADC space heating up, it's clear Merck is positioning itself for targeted growth! 🚀 #Merck #KelunBiotech #ADC #PharmaNews #Biotech #CancerResearch #Oncology #DrugDevelopment #HealthcareInnovation #PipelineUpdate #LinkedInNews

2

1 Comment

🔬 Attention U.S. Biotech and Pharma Professionals: Major Industry Shifts on the Horizon? 🧪 The ongoing scrutiny of Chinese CDMOs, particularly WuXi AppTec, could reshape our industry landscape. Here's what you need to know: 1. The BIOSECURE Act, if passed, could force U.S. drugmakers to cut ties with certain Chinese biotech companies by 2032. This affects over 120 U.S. biopharma drugs currently partnered with these firms. 2. WuXi AppTec's deep integration in U.S. pharma (involved in developing ~25% of drugs used in the U.S.) means any restrictions could have far-reaching effects on drug development pipelines. 3. Indian CDMOs are positioning themselves to potentially fill the gap. With a market estimated at $22 billion and growing, they're ramping up investments in capacity and capabilities. 4. However, challenges remain. Indian CDMOs may face hurdles in small molecule production and need to address quality concerns. 5. We might see a push towards domestic U.S. CDMOs as concerns grow about offshore dependencies. As industry professionals, we need to stay ahead of these potential shifts. How is your organization preparing for possible changes in the CDMO landscape? #Biotech #Pharma #CDMO #DrugDevelopment #RegulatoryChanges

6

Let’s hope this is a big step forward by anticipating and addressing potential regulatory backlog given the inflection of #cellandgene therapy and #AI approaches. The logic being that a standardized framework for development platforms could take less assessment time and offer #biotech swifter approvals and reduced development costs. #innovation #medicine #pharmaceutical #

5

The results from Arrowhead Pharmaceuticals' Phase 3 PALISADE study on plozasiran are truly impressive and could be a game-changer for patients with familial chylomicronemia syndrome (FCS). I'm excited by the potential impact this could have on a condition that currently has no approved treatments in the U.S. The involvement of experts like Gerald F. Watts and Bruce Given, M.D. adds significant weight to these findings. Their work not only showcases the power of RNAi therapeutics but also highlights how targeted innovation can meet critical, unmet medical needs. If plozasiran is approved, it could dramatically improve the quality of life for FCS patients, and it’s exciting to see this kind of progress in the field. #RNAi #FCS #research #Biotechnology

6

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐬𝐢𝐭𝐞𝐬 𝐬𝐞𝐞𝐧 𝐚𝐬 𝐡𝐨𝐭 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐲 𝐟𝐨𝐫 𝐏𝐄 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 Private equity is increasingly investing in clinical trial sites due to industry demand for larger networks, as shown by PitchBook's analysis of first quarter 2024 deal activity. Contract research organizations (CROs) are acquiring trial sites to enhance their service offerings, exemplified by American Clinical Research Services acquiring Elixia and Alcanza Clinical Research's focus on sites in Hispanic areas. This trend is part of a broader movement towards vertical and horizontal consolidation, aiming to create end-to-end drug development capabilities. #privateequity #clinicalresearchsites

4

Rivus Pharmaceuticals is making waves in biotech with its innovative approach to weight loss for heart failure patients. Unlike existing therapies, their drug HU6 targets fat loss without sacrificing muscle mass—crucial for frail patients. This novel mechanism could redefine treatment options for heart failure with preserved ejection fraction (HFpEF) and other metabolic diseases. With the weight loss market booming and Rivus poised for a Phase III study, this is one company to watch as it tackles high-burden diseases with groundbreaking science. This could be the next leap forward in cardiometabolic health! Jayson Dallas University of Texas Southwestern Medical Center Ambarish Pandey GlobalData Healthcare Novo Nordisk Lars Fruergaard Jørgensen Eli Lilly and Company Dave Ricks #Biotech #Pharma #Innovation #CardiometabolicHealth #ClinicalTrials #WeightLoss #HeartFailure #PharmaInnovation #MetabolicHealth #ObesityResearch #Biotechnology

1

1 Comment

📣 For those going to the ASA Biopharmaceutical Section Statistics Workshop this week, Stop by Booth #18 to meet my teammates: Lei Wang, Helena Fan, & Bill Emker. American Statistical Association - ASA #pharma #fda #statistics #statisticians #biostatisticians #biostatistics #datascience

1